ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $237,846 | -1.0% | 2,540 | -5.6% | 0.01% | 0.0% |
| Q2 2023 | $240,172 | -30.1% | 2,691 | -16.0% | 0.01% | -38.1% |
| Q1 2023 | $343,640 | -4.9% | 3,205 | +8.3% | 0.02% | -8.7% |
| Q4 2022 | $361,505 | -27.4% | 2,960 | -5.2% | 0.02% | +35.3% |
| Q3 2021 | $498,000 | +26.7% | 3,124 | +4.4% | 0.02% | +30.8% |
| Q2 2021 | $393,000 | – | 2,991 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |